Commercial pharmaceutical partner, Inovail, successfully launches
OmegaGen(R) in Australia and New Zealand
LAVAL, QC, March 25 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) and its commercial pharmaceutical partner Inovail Pty Ltd ("Inovail"), announce the successful launch of OmegaGen(R) as a complementary medicine in Australia and New Zealand. Neptune foresees this market entry as a commercial portal for Neptune into large medicinal Asian Pacific markets.
Inovail in collaboration with PharmaLink, which ranks amongst the top five sales organizations in the Australian pharmaceutical industry, is promoting and marketing OmegaGen(R). OmegaGen(R), containing Neptune Krill Oil (NKO(R)), is being initially distributed through retail pharmacies, health food stores and healthcare professionals. As a short-term marketing objective, Inovail seeks to distribute OmegaGen(R) in three thousand pharmacies.
"Our strong clinical evidence and established credibility in the industry will help Inovail's brands achieve high levels of medical endorsement as natural, evidence-based options for the improvement of cognitive function, and chronic cholesterol and inflammation management," said Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Additional product launches to expand the complementary medicine franchise are planned in the following few months. This strategy should allow Neptune to take full advantage of these products in a combined potential market worth over 300 million$."
"We are very excited to be the first to launch Neptune Krill Oil, an
exceptional and innovative product. We expect to gain rapid and deep
penetration of the pharmacy and other healthcare channels," said Dr. Peter
Mayrick from Inovail. "Our market research has indicated that, when health
professionals and consumers of omega-3 fatty acids are presented the
clinical evidence for Neptune Krill
|SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.|
Copyright©2008 PR Newswire.
All rights reserved